COVID-19 vaccines stories

Otsuka's VOYXACT Shows Kidney Function Stabilization in Phase 3 Trial; BioNTech Cuts Revenue Forecast on Weak COVID Vaccine Demand

Otsuka announced two-year Phase 3 VISIONARY trial results showing VOYXACT (sibeprenlimab-szsi) stabilized kidney function decline in IgA nephropathy patients, with annual eGFR slope of +0.3 versus -4.2 for placebo. Separately, BioNTech lowered its 2026 revenue guidance by €400 million to €1.6-1.9 billion due to declining COVID-19 vaccine demand.